Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 70Neoplasms 13Neoplasm Metastasis 7Brain Neoplasms 7Head and Neck Neoplasms 6Breast Neoplasms, Male 6Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Osteitis Deformans 2Neuroma, Acoustic 2Neurofibromatosis 2 2Inflammatory Breast Neoplasms 2Glioblastoma 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × HER2 Positive Esophagogastric Cancer × Lapatinib × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡